TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01162421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
Study: NCT01357850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155
Description: GSK716155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155
Description: GSK716155
Study: NCT01162421

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
Study: NCT01357850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155
Description: GSK716155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00792571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Study: NCT00593476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCD
Description: pre-packaged, portion-controlled (PCD) meal plan for 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DSE
Description: 12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
Study: NCT04153708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.
Description: Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter
Description: Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
Study: NCT04567901

Intervention type: OTHER
Intervention: Death
Description: Mortality group

Intervention type: OTHER
Intervention: Survive
Description: Survival group
Study: NCT00737451

Intervention type: BEHAVIORAL
Intervention: blood sampling
Description: blood sampling 10ml from the study subjects
Study: NCT00002909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sodium phenylbutyrate
Study: NCT02175056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL2351
Description: Dose-escalation For 5 level dose groups A \~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HL2351
Description: Dose-escalation For 5 level dose groups A \~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Kineret(Anakinra)
Description: Active comparator(group F) is implemented in parallel with dose groups A\~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
Study: NCT02163174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline (PTX)
Description: Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
Study: NCT04195828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
Study: NCT01249352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200 mg, IV Weekly IV dose for up to 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: 200 mg, IV Weekly IV dose for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
Study: NCT02147483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment usually provided by clinician
Study: NCT05664165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold spray and stretching
Description: The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied.
Study: NCT03183674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Single dose oxytocin 45 minutes before the test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline solution 0,9% spray nasal
Study: NCT00848354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase 1: Etanercept
Description: Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Methotrexate
Description: Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: Optional ETN, SSZ, HCQ, MTX
Description: Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1: Methotrexate
Description: Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1: Conventiaonal DMARD
Description: Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
Study: NCT05788939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned Visual Education Based on Health Belief Model
Description: The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~.
Study: NCT00609596

Intervention type: DRUG
Group type: OTHER
Intervention: GI198745
Study: NCT02604940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
Study: NCT01507376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant hCG
Description: recombinant hCG(250 µg Ovitrell)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant hCG
Description: recombinant hCG(500 µg Ovitrell)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urinary hCG
Description: 10,000 IU urinary hCG
Study: NCT01407783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Tools (PST)
Description: The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
Study: NCT03949270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BETA-Text text messaging intervention
Description: Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
Study: NCT02394977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression with Feedback
Description: Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard chest compression
Description: CPR in accordance with published international guidelines using standard manual chest compression.
Study: NCT00874250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE CTAG Device
Description: Endovascular aortic stent-graft
Study: NCT05630287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Selpercatinib
Description: Administered as an oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Selpercatinib
Description: Administered intravenously
Study: NCT01657578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: administration of Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: administration of Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: administration of Omeprazole
Study: NCT02445586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Study: NCT03550066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values affirmation
Description: A health message with a prompt asking participants to reflect on important personal values

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No affirmation
Description: A health message alone
Study: NCT01833884

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood specimen
Description: Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
Study: NCT02635971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT01604005

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Irradiation of Tracts (PIT)
Description: 21 Gy in 3 fractions
Study: NCT02439658

Intervention type: DRUG
Intervention: Dofetilide and/or sotalol
Description: This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.

Intervention type: DRUG
Intervention: Dofetilide and/or sotalol
Description: This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
Study: NCT01284166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
Description: 1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
Study: NCT03923205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
Study: NCT04121247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmacological approaches to parents of children with sickle cell disease training program
Description: use of non-pharmacological approaches in children with sickle cell disease, parent education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmacological approaches to parents of children with sickle cell disease training program
Description: use of non-pharmacological approaches in children with sickle cell disease, parent education
Study: NCT03436186

Intervention type: OTHER
Description: no intervention
Study: NCT01002079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, Once daily, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, Once daily, 1 day

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin
Description: Capsule, Oral, 600 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Capsule, Oral, 600 mg, Once daily, 6 days
Study: NCT04665830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: treated patients with evolocumab for high cholesterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evolocumab
Description: treated patients with evolocumab for high cholesterol
Study: NCT01150266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (tPA)
Description: 0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
Study: NCT01612715

Intervention type: OTHER
Intervention: Segmental Allergen Challenge
Description: segmental allergen challenge
Study: NCT00146263

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Savyon
Description: Computerized cognitive training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual activity
Study: NCT02674438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk stratification and transitional care intervention
Description: Intervention consists of 2 components:~1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge.
Study: NCT01016639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine, radiotherapy
Study: NCT04003688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate through real weight group
Description: Magnesium sulfate dose 40 mg/kg of actual patient's weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Saline solution (instead of magnesium sulfate, as in the other groups)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate through ideal corrected weight group
Description: Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
Study: NCT03751865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
Study: NCT01448200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-668
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules